Larimar Therapeutics prices 20M share public offering at $5.00 per share; underwriters exercise over-allotment

Larimar Therapeutics, Inc.

Offering of 20,000,000 shares plus 3,000,000 over-allotment shares at $5.00 per share.
Net proceeds after underwriting discounts and expenses expected to be approx. $107.6M.
Underwriters include J.P. Morgan, Guggenheim, LifeSci Capital, William Blair, and others.
Offering expected to close on February 27, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Larimar Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Guggenheim Securities, LLC valued at 20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds (effective 2026-02-25).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC and Guggenheim Securities, LLC
Value: 20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds
Effective: 2026-02-25

Exact text from the filing

On February 25, 2026, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 20,000,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $5.00 per share (the “ Offering ”).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-077646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.